Lonnie Moulder

Ex­clu­sive: Two M&A deals and $9B lat­er, Lon­nie Moul­der is ramp­ing up his lat­est biotech start­up. And this one comes with glob­al vi­sion built in

Lon­nie Moul­der may have been in silent run­ning mode in the 2 years since he closed the $5 bil­lion sale of Tesaro to Glax­o­SmithK­line. But he hasn’t been idle.

To­day dur­ing the Chi­na Health­care In­vest­ment Con­fer­ence in Shang­hai, where End­points News is play­ing a co-spon­sor role, Moul­der’s tak­ing the wraps off a biotech start­up he’s put to­geth­er that has as­sem­bled a pipeline with 7 drugs in it, a plan to add sev­er­al more ther­a­pies and a quick vault in­to the clin­ic for a com­pa­ny with a small but fast-ex­pand­ing team that is grow­ing roots in Chi­na and the US — with Eu­rope soon to be added to its glob­al frame.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.